Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Search

Top

CROSSJECT SA

UEI: NLXZHCL3NLL3CAGE: FBEF0

CROSSJECT SA is a federal contractor, registered under UEI NLXZHCL3NLL3 and CAGE code FBEF0. It has been awarded $108,841,770 in federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Websitehttp://www.crossject.com

Address123 Main St, City, ST 12345

Registration

UEI Code

NLXZHCL3NLL3

CAGE Code

FBEF0

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationManufacturer of Goods

NAICS Codes

325411Medicinal and Botanical Manufacturing

325412Pharmaceutical Preparation Manufacturing

325414Biological Product (except Diagnostic) Manufacturing

541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

CROSSJECT SA specializes in the advanced research, development, and delivery of biotechnological medical countermeasures, with a focused expertise in autoinjector systems for acute neurological emergencies. Their technical capabilities center on the design, formulation, and regulatory pathways for a...

Key Performance Metrics

Awards Count

1

All time

Active

1

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Health And Human Services$108.8M100%

Awards by NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)$108.8M100%

Awards by Agency Over Time

Awards by Place of Performance

Compete with CROSSJECT SA

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for CROSSJECT SA

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Join 750+ contractors already using CLEATUS

Open opportunities in CROSSJECT SA's top NAICS codes and agencies

In Vivo Biodistribution Studies and Bioluminescence ImagingThis subcontract, titled In Vivo Biodistribution Studies and Bioluminescence Imaging, supports biotechnology projects for the Department of Veterans Affairs at the Harry S Truman Memorial Veterans Hospital. The selected provider will conduct animal studies to evaluate AAV vector specificity and off-target transduction. Key technical responsibilities include administering vectors to animal models, utilizing bioluminescence imaging via IVIS to track localization, and performing tissue harvesting for qPCR analysis to generate comprehensive biodistribution data reports. The work will be performed in Columbia, Missouri, and requires strict adherence to AAALAC and FELASA health standards. This opportunity is categorized under NAICS code 541714 and is managed by Rpo East. Interested parties should note the response deadline of November 4, 2026.

Rpo East (36C24E)

POSTED

about 11 hours ago

DEADLINE

AAV Vector Binding and Internalization Testing (Kidney Tissue)This subcontract, issued by the Department of Veterans Affairs Rpo East for biotechnology projects at the Harry S Truman Memorial Veterans Hospital, involves specialized laboratory testing to verify the binding and internalization of AAV vectors. The selected provider will be responsible for preparing kidney tissue slices, incubating them with modified AAV vectors, and utilizing qPCR platforms, Agilent Fragment Analyzers, and fluorescence microscopy to analyze efficiency. All work must be performed in BSL-2 facilities, and the contractor is required to hold BSL-2 certification. The primary deliverable for this engagement is the provision of detailed validation reports focusing on internalization rates and binding affinity. The project is categorized under NAICS code 541714 and is based in Columbia, Missouri. Interested parties must respond by November 4, 2026.

Rpo East (36C24E)

POSTED

about 11 hours ago

DEADLINE

AJ12--Development/Production - Kidney GEC-Specific AAV Vector

Solicitation # 36C24E27Q0009

The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.

Rpo East (36C24E)

POSTED

about 11 hours ago

DEADLINE

MPS Platform Development & EngineeringThis subcontract focuses on the development and engineering of Microphysiological Systems and Organ-on-a-Chip platforms to support prime contractors on NIH/NIAID infectious disease projects. The scope of work involves engineering microfluidic devices, optimizing tissue-chip interfaces, and utilizing biocompatible polymers and precision pumps to integrate human variability into hardware and biological interfaces. The ultimate goal is to deliver a validated and reproducible platform that aligns with NIH and FDA guidance regarding New Approach Methodologies. Managed under the National Institutes of Health within the Department of Health and Human Services, the project falls under NAICS code 541714. The solicitation was posted on October 20, 2026, with a response deadline set for January 29, 2027.

National Institutes Of Health

POSTED

DEADLINE

Discovery Gateway to Reproductive Health InnovationThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to establish the Discovery Gateway to Reproductive Health Innovation. This initiative aims to create a comprehensive, open-access web-based visualization platform and knowledgebase to advance research on male and female reproductive health issues, including infertility, uterine fibroids, endometriosis, preeclampsia, and preterm birth. By integrating multi-omic, pharmacogenomic, and clinical data, the Gateway seeks to fill critical knowledge gaps and provide the biomedical community with shared infrastructure to identify biomarkers, drug targets, and disease mechanisms. The primary objective of this project is to catalyze the discovery of new treatments and cures while fostering public-private partnerships and the development of commercial products. This effort aligns with recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. The opportunity is currently listed as a forecast, with administrative oversight provided by the Obstetric and Pediatric Pharmacology and Therapeutics Branch.

National Institutes Of Health

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking applications under solicitation RFA-AI-28-005 to continue the Immune Tolerance Network. The primary goal of this initiative is the development of tolerogenic therapies targeting autoimmune diseases, allergic diseases and asthma, and immune-mediated consequences of transplantation. The network is tasked with the core functions of designing and conducting clinical trials, performing integrated mechanistic studies, and sharing the resulting data. This federal solicitation was posted on October 20, 2026, and requires responses by January 30, 2027. As a UM1 clinical trial requirement, the project emphasizes a collaborative approach to advancing medical treatments for immune-mediated disorders through rigorous clinical research and analysis.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is soliciting proposals for the Translational Centers Using Microphysiological Systems for Infectious Diseases under solicitation number RFA-AI-28-012. This initiative aims to establish a consortium of centers focused on refining and validating human tissue models to study infectious diseases and test medical interventions. By leveraging New Approach Methodologies, the program seeks to create in vitro systems that capture human variability and patient-specific characteristics, ultimately accelerating the development of safer treatments while reducing costs and the reliance on laboratory animals. The primary objective is to advance these microphysiological systems to a level of regulatory qualification that encourages adoption by product developers and ensures regulatory acceptance. Interested parties must submit their responses by the deadline of January 30, 2027. This federal opportunity specifically focuses on bridging the gap between current research and regulatory use for infectious disease models, though it is noted that clinical trials are not allowed under this specific funding mechanism.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Barley Net Blotch Initiative (BNBI) Program 2 – Host and pathogen genetics

Solicitation # PROC-9177507

The Grains Research and Development Corporation is seeking a partner to deliver Program 2 of the Barley Net Blotch Initiative, a five-year national effort to combat the significant economic threat of net blotch in Australian barley. This specific program focuses on host and pathogen genetics to fast-track the development of durable host resistance. Key objectives include providing breeder-deployable validated markers, characterizing resistance sources, conducting pathogenic genomics research, establishing a durability risk-assessment framework, and assessing the feasibility of genome-editing. This solicitation, identified as PROC-9177507, was posted on October 19, 2026, with a response deadline of March 4, 2027. The project is part of a broader strategy involving pathogen surveillance and integrated disease management to reduce the estimated 122 million dollar annual loss caused by yield decreases and grain quality downgrades. Performance of the contract will span multiple major Australian cities, including Canberra, Sydney, Melbourne, Adelaide, Perth, Brisbane, Darwin, and Hobart.

Grains Research and Development Corporation

POSTED

DEADLINE

Pre-Clinical Models of Infectious Diseases

Solicitation # 75N93027R00003

The National Institute of Allergy and Infectious Diseases (NIAID) is issuing a ramp-on solicitation to award multiple IDIQ base contracts for the Preclinical Models of Infectious Diseases program. This initiative aims to expand the existing pool of contractors capable of developing and refining animal and animal replacement models to evaluate medical countermeasures, such as vaccines, therapeutics, and diagnostics. The program bridges the gap between in vitro testing and clinical evaluation, supporting regulatory submissions and the advancement of countermeasures against priority biodefense and emerging infectious agents. Successful offerors will be eligible to compete for task orders across four specific areas: Small Animal Models, Non-Human Primate Models, Animal Replacement and Non-traditional Animal Models, and the Generation and Distribution of Specialized Reagents. The scope of work emphasizes a wide array of pathogens, including pandemic-potential RNA viruses, antimicrobial-resistant infections, fungal diseases, and neglected tropical diseases. Proposals must be submitted electronically via the NIAID eCPS website, and applicants are required to have a valid NIH eRA Commons account for authentication and secure transmission.

National Institutes Of Health Niaid

POSTED

DEADLINE

in about 2 months

Alternative Protein Technologies for Military Field Feeding

Solicitation # W911QY27ALTPROTEINS

The US Army Combat Capabilities Development Command Soldier Center is seeking information from Massachusetts-based offerors to identify innovative alternative protein technologies for integration into military rations. The objective is to enhance food supply chain resilience and provide nutrient-dense, lightweight food options for warfighters. Areas of interest include fermentation and biomanufacturing processes, innovative product development for shelf-stable rations, consumer research for military acceptability, and the optional provision of GRAS-certified food samples. Specifically, the government is excluding any solutions involving cell-cultured, lab-grown meat, or insect proteins, focusing instead on technologies between TRL 4 and 6. This is a Sources Sought Announcement for market research purposes and not a formal solicitation or a promise of future funding. Interested parties must submit a BAA preproposal by November 23, 2026, including a technical approach, past performance, and a rough order of magnitude cost estimate. Submissions must be sent via email to the designated points of contact and include the offeror's business size, NAICS code, and CAGE code to verify their Massachusetts location.

W6QK Acc-Apg Natick

POSTED

DEADLINE

in about 1 month

USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology

Solicitation # USDA-NIFA-TOPIC-8.2

The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.

National Institute of Food and Agriculture

POSTED

DEADLINE

Artificial Blood and Medical Consumable InnovationThe Artificial Blood and Medical Consumable Innovation subcontract supports the Defense Advanced Research Projects Agency within the Department of Defense. The scope of work involves providing innovative medical consumables and conducting biochemical research specifically focused on the development of artificial blood for prime contractors on DARPA Biological Technologies Office projects. The contractor is responsible for engineering scalable manufacturing processes for these consumables using sterile manufacturing facilities and bio-reactors. Key deliverables include the production of artificial blood prototypes and the implementation of scalable medical consumable solutions. This effort falls under NAICS code 541714, with a response deadline set for November 15, 2026.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Pre-Award Synopsis Texas Shield

Solicitation # DARPA-SN-27-07

The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), intends to enter into an agreement with The University of Texas System consortium of universities for the Texas Shield Program. This integrated research initiative, identified by solicitation number DARPA-SN-27-07 and NAICS code 541714, focuses on developing autonomous and semi-autonomous medical technologies and scalable solutions for critical medical consumables. The primary goal is to support lifesaving medical care in contested, austere, and resource-limited environments. Key technical areas of focus include autonomous medical and robotic surgical systems, casualty evacuation, artificial-blood and supply innovation, AI-enabled clinical decision support, and mass-casualty science and simulation. This notice is a pre-award synopsis and is not a request for proposals or a competitive solicitation. Interested entities are invited to submit information by November 15, 2026, to TexasShieldxBTO@darpa.mil detailing their technical expertise, integrated research infrastructure, clinical-validation capabilities, and multi-institutional coordination capacity. Additionally, respondents must describe their consortium organizational structure, commercialization capabilities, facility clearance levels, and their ability to handle Controlled Unclassified Information. The government will not reimburse any costs associated with the preparation or submission of information in response to this notice.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Q--AMPLICON SEQUENCING SERVICES

Solicitation # 140G0226Q0047

Solicitation 140G0226Q0047 is a firm-fixed-price request for a Blanket Purchase Agreement (BPA) to provide next generation amplicon sequencing services for the USGS Upper Midwest Water Science Center’s Michigan Bacteriological Research Laboratory. The scope of work includes providing all equipment, labor, travel, and materials necessary to support research on bacterial pathogens, harmful algal blooms, microbial ecology, antibiotic resistance, and microbial source tracking. Key technical requirements include the use of Illumina MiSeq or AVITI sequencing technologies and the potential for library preparation for 16S V4 amplicon sequencing. The BPA has a total not-to-exceed value of 250,000 dollars with an estimated period of performance from September 17, 2026, to September 16, 2031. The award process prioritizes non-priced factors significantly over cost, focusing on the offeror's qualifications and technical performance. Evaluation criteria include a detailed listing of on-site equipment and calibration dates, personnel experience, internal quality assurance procedures, and a technical narrative not exceeding two pages. Performance will be executed in Lansing, Michigan, with delivery terms set as FOB Destination. Administrative requirements include electronic invoicing via the Internet Payment Platform and compliance with various federal regulations, including the Buy American Act and specific security prohibitions regarding telecommunications equipment. Proposals must be submitted to the USGS OAG Denver Acquisition Branch by September 11, 2026.

Ofc Of Acquisition Grants-Denver

POSTED

DEADLINE

RFI Lupus Research Program (LRP) Public

Solicitation # HT9427RFI2027LRP

The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information regarding the Lupus Research Program for fiscal year 2027. This action is strictly for information and planning purposes to identify future research focus areas and funding opportunities; it is not a solicitation, and no contracts will be awarded based on this announcement. The program aims to cure lupus by funding research to improve diagnosis, prevention, and treatment, with a specific focus on understanding biological or genetic patient subsets, disease mechanisms, and enhancing overall patient quality of life. Interested parties from academia, industry, non-profit organizations, and the public are invited to provide feedback on critical research gaps and underfunded areas. Responses must be submitted via Survey Monkey by November 16, 2026. While historical appropriations from fiscal years 2017 through 2024 and 2026 totaled 75 million dollars, funds for fiscal year 2027 have not yet been appropriated. Respondents are cautioned not to submit proprietary or sensitive information through the survey portal, as the government cannot protect such data, and all costs associated with responding to this request are the responsibility of the participant.

Defense Health Agency

POSTED

DEADLINE

Clinical Trial Site Operations and Participant ManagementThis subcontract for Clinical Trial Site Operations and Participant Management supports prime contractors on NIH/NIDDK projects through the direct execution of clinical trials. The scope of work includes recruiting and enrolling study participants, implementing lifestyle intervention weight loss programs, and conducting scheduled study visits and clinical procedures. To ensure compliance and quality, the provider must maintain IRB approval, active SAM/eRA Commons registration, and utilize specialized clinical trial facilities equipped with medical-grade ultra-low temperature freezers for biospecimen storage. The primary deliverables for this engagement consist of completed participant visits, curated patient data, and the collection of biospecimens. This opportunity is associated with NAICS code 541714 and falls under the jurisdiction of the National Institutes of Health within the Department of Health and Human Services. The response deadline for this requirement is November 17, 2026.

National Institutes Of Health

POSTED

DEADLINE